Leerink Partnrs Brokers Lift Earnings Estimates for Xencor

Xencor, Inc. (NASDAQ:XNCR) – Investment analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of Xencor in a report issued on Thursday, November 7th. Leerink Partnrs analyst J. Chang now expects that the biopharmaceutical company will earn ($3.96) per share for the year, up from their prior forecast of ($4.36). The consensus estimate for Xencor’s current full-year earnings is ($3.91) per share. Leerink Partnrs also issued estimates for Xencor’s Q4 2024 earnings at ($1.07) EPS and FY2025 earnings at ($3.40) EPS.

Xencor (NASDAQ:XNCR) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $10.70 million for the quarter, compared to the consensus estimate of $14.59 million. During the same quarter in the prior year, the company earned ($0.40) EPS. The firm’s quarterly revenue was down 81.9% on a year-over-year basis.

A number of other equities analysts also recently commented on the company. JPMorgan Chase & Co. increased their price objective on Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Royal Bank of Canada increased their price objective on Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, September 26th. BMO Capital Markets restated an “outperform” rating and issued a $34.00 price objective (up previously from $32.00) on shares of Xencor in a report on Friday. Finally, Wedbush restated an “outperform” rating and issued a $38.00 price objective on shares of Xencor in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $35.75.

Xencor Trading Down 1.3 %

NASDAQ:XNCR opened at $23.31 on Monday. The stock’s 50 day moving average price is $20.45 and its 200 day moving average price is $20.29. Xencor has a 52 week low of $15.31 and a 52 week high of $26.84. The company has a market capitalization of $1.63 billion, a P/E ratio of -7.28 and a beta of 0.66. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.92 and a current ratio of 6.23.

Institutional Investors Weigh In On Xencor

Several hedge funds have recently modified their holdings of the business. Texas Permanent School Fund Corp boosted its position in shares of Xencor by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 53,277 shares of the biopharmaceutical company’s stock valued at $1,179,000 after acquiring an additional 690 shares during the period. Linden Thomas Advisory Services LLC boosted its position in shares of Xencor by 1.6% in the second quarter. Linden Thomas Advisory Services LLC now owns 43,643 shares of the biopharmaceutical company’s stock valued at $826,000 after acquiring an additional 699 shares during the period. Baillie Gifford & Co. boosted its position in shares of Xencor by 3.3% in the second quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company’s stock valued at $445,000 after acquiring an additional 744 shares during the period. Louisiana State Employees Retirement System boosted its position in shares of Xencor by 3.0% in the second quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company’s stock valued at $587,000 after acquiring an additional 900 shares during the period. Finally, Diversified Trust Co boosted its position in shares of Xencor by 7.8% in the second quarter. Diversified Trust Co now owns 14,076 shares of the biopharmaceutical company’s stock valued at $266,000 after acquiring an additional 1,017 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.